BioCentury
ARTICLE | Company News

IBA Group, Wilex deal

May 12, 2014 7:00 AM UTC

Wilex and IBA terminated a 2008 deal granting IBA an exclusive, worldwide license to commercialize Wilex's Redectane. All rights reverted back to Wilex. Redectane, a radiolabeled WX-G250 antibody, has completed one Phase III trial as a diagnostic imaging agent for clear cell renal cell carcinoma (RCC). Wilex said it is plans to seek partners to finance, develop and commercialize Redectane externally (see BioCentury, June 16, 2008). ...